177 related articles for article (PubMed ID: 24887547)
1. A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions.
Brunner AL; Li J; Guo X; Sweeney RT; Varma S; Zhu SX; Li R; Tibshirani R; West RB
Genome Biol; 2014 May; 15(5):R71. PubMed ID: 24887547
[TBL] [Abstract][Full Text] [Related]
2. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
3. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
4. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
5. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee JY; Park YJ; Oh N; Kwack KB; Park KS
Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
[TBL] [Abstract][Full Text] [Related]
6. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M; Dowhan DH
Neoplasia; 2012 Apr; 14(4):283-96. PubMed ID: 22577344
[TBL] [Abstract][Full Text] [Related]
7. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
Ding Y; Liu Y; Lee DK; Tong Z; Yu X; Li Y; Xu Y; Lanz RB; O'Malley BW; Xu J
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006643
[TBL] [Abstract][Full Text] [Related]
8. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
Kong SL; Li G; Loh SL; Sung WK; Liu ET
Mol Syst Biol; 2011 Aug; 7():526. PubMed ID: 21878914
[TBL] [Abstract][Full Text] [Related]
9. Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer.
Schneider J; Ruschhaupt M; Buness A; Asslaber M; Regitnig P; Zatloukal K; Schippinger W; Ploner F; Poustka A; Sültmann H
Int J Cancer; 2006 Dec; 119(12):2974-9. PubMed ID: 17019712
[TBL] [Abstract][Full Text] [Related]
10. The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer.
Martin EM; Orlando KA; Yokobori K; Wade PA
Curr Opin Struct Biol; 2021 Dec; 71():65-70. PubMed ID: 34225008
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
12. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
[TBL] [Abstract][Full Text] [Related]
13. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
14. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.
Bong PN; Zakaria Z; Muhammad R; Abdullah N; Ibrahim N; Emran NA; Syed Hussain SN
Malays J Pathol; 2010 Dec; 32(2):117-22. PubMed ID: 21329183
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 in breast cancer.
Nakshatri H; Badve S
Expert Rev Mol Med; 2009 Mar; 11():e8. PubMed ID: 19261198
[TBL] [Abstract][Full Text] [Related]
16. Genome-Wide Transcriptome Analysis of Estrogen Receptor-Positive and Human Epithelial Growth Factor Receptor 2-Positive Breast Cancers by Ribonucleic Acid Sequencing.
Chen P; Song W; Liu L
Gynecol Obstet Invest; 2018; 83(4):338-348. PubMed ID: 29241203
[TBL] [Abstract][Full Text] [Related]
17. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER
Gawrzak S; Rinaldi L; Gregorio S; Arenas EJ; Salvador F; Urosevic J; Figueras-Puig C; Rojo F; Del Barco Barrantes I; Cejalvo JM; Palafox M; Guiu M; Berenguer-Llergo A; Symeonidi A; Bellmunt A; Kalafatovic D; Arnal-Estapé A; Fernández E; Müllauer B; Groeneveld R; Slobodnyuk K; Stephan-Otto Attolini C; Saura C; Arribas J; Cortes J; Rovira A; Muñoz M; Lluch A; Serra V; Albanell J; Prat A; Nebreda AR; Benitah SA; Gomis RR
Nat Cell Biol; 2018 Feb; 20(2):211-221. PubMed ID: 29358704
[TBL] [Abstract][Full Text] [Related]
18. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
19. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.
Buchwalter G; Hickey MM; Cromer A; Selfors LM; Gunawardane RN; Frishman J; Jeselsohn R; Lim E; Chi D; Fu X; Schiff R; Brown M; Brugge JS
Cancer Cell; 2013 Jun; 23(6):753-67. PubMed ID: 23764000
[TBL] [Abstract][Full Text] [Related]
20. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
